MiMedx (MDXG) 10-Q 1 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 15, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	MIMEDX GROUP, INC.
Entity Central Index Key	1376339
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		108,630,057
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$38,696	$46,582
Short term investments	6,000	5,750
Accounts receivable, net	31,001	26,672
Inventory, net	4,248	5,133
Prepaid expenses and other current assets	2,341	1,540
Total current assets	82,286	85,677
Investments	2,500	3,250
Property and equipment, net of accumulated depreciation	6,440	5,447
Goodwill	4,040	4,040
Intangible assets, net of accumulated amortization	10,813	10,845
Other assets	26	0
Total assets	106,105	109,259
Current liabilities:
Accounts payable	5,379	3,661
Accrued compensation	8,720	11,523
Accrued expenses	3,615	2,504
Other current liabilities	746	716
Total current liabilities	18,460	18,404
Other liabilities	1,244	1,526
Total liabilities	19,704	19,930
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding	0	0
Common stock; $.001 par value; 130,000,000 shares authorized; 109,468,759 issued and 108,491,478 outstanding at March 31, 2015 and 108,776,247 issued and 107,789,611 outstanding at December 31, 2014	109	108
Additional paid-in capital	158,401	162,433
Treasury stock at cost: 977,281 shares at March 31, 2015 and 986,636 shares at December 31, 2014	-8,621	-5,637
Accumulated deficit	-63,488	-67,575
Total stockholders' equity	86,401	89,329
Total liabilities and stockholders' equity	$106,105	$109,259

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Net sales	$40,767	$19,559
Cost of sales	5,148	2,977
Gross margin	35,619	16,582
Operating expenses:
Research and development expenses	1,831	1,390
Selling, general and administrative expenses	29,308	15,852
Amortization of intangible assets	233	231
Operating income (loss)	4,247	-891
Other income (expense), net
Interest expense, net	-14	-21
Income (loss) before income tax provision	4,233	-912
Income tax provision	-146	-10
Net Income (loss)	$4,087	($922)
Net income (loss) per common share - basic	$0.04	($0.01)
Net income (loss) per common share - diluted	$0.04	($0.01)
Weighted average shares outstanding - basic	105,820,335	105,358,694
Weighted average shares outstanding - diluted	113,638,551	105,358,694

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	130,000,000	130,000,000
Common stock, shares issued (in shares)	109,468,759	108,776,247
Common stock, shares outstanding (in shares)	108,491,478	107,789,611
Treasury stock, shares (in shares)	977,281	986,636

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) (USD $)	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit
In Thousands, except Share data, unless otherwise specified
Balance at Dec. 31, 2014	$89,329	$108	$162,433	($5,637)	($67,575)
Balance (in shares) at Dec. 31, 2014		108,776,247		986,636
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	3,933		3,933
Exercise of stock options	1,276	1	222	1,053
Exercise of stock options (in shares)	760,156	647,656		-112,500
Exercise of warrants	0
Exercise of warrants (in shares)		0		0
Issuance of restricted stock	0		-8,258	8,258
Restricted stock shares cancelled/forfeited (in shares)		-715
Issuance of restricted stock (in shares)		34,250		-1,256,608
Shares issued for services performed	71		71
Shares issued for services performed (in shares)	11,321	11,321
Stock repurchase	-12,295			-12,295
Stock repurchase (in shares)	1,359,753			1,359,753
Net income (loss)	4,087				4,087
Balance at Mar. 31, 2015	$86,401	$109	$158,401	($8,621)	($63,488)
Balance (in shares) at Mar. 31, 2015		109,468,759		977,281

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income	$4,087	($922)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation	354	263
Amortization of intangible assets	233	231
Share-based compensation	3,933	2,372
Increase (decrease) in cash resulting from changes in:
Accounts receivable	-4,329	-2,874
Inventory	885	242
Prepaid expenses and other current assets	-801	-942
Other assets	-26	0
Accounts payable	1,789	128
Accrued compensation	-2,803	-175
Accrued expenses	1,111	-37
Other liabilities	-223	102
Net cash flows from operating activities	4,210	-1,612
Cash flows from investing activities:
Purchases of equipment	-1,347	-466
Proceeds from Sale and Maturity of Held-to-maturity Securities	500	0
Patent application costs	-201	-168
Net cash flows from investing activities	-1,048	-634
Cash flows from financing activities:
Proceeds from exercise of stock options	1,276	445
Proceeds from exercise of warrants	0	775
Stock repurchase	-12,295	0
Payments under capital lease obligations	-29	-33
Net cash flows from financing activities	-11,048	1,187
Net change in cash	-7,886	-1,059
Cash and cash equivalents, beginning of period	46,582	44,078
Cash and cash equivalents, end of period	$38,696	$43,019

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the three months ended March 31, 2015 and 2014, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2014, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
	You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2014, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015.
	The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The Company's biomaterial platform technologies include tissue technologies, AmnioFix® and EpiFix®, and device technology, CollaFix™, which the Company has yet to commercialize.

Significant_Accounting_Policie

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies
	Please see Note 2 to the Company's Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2014, for a description of all significant accounting policies.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Accounts Receivable
	Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
	The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.
	Inventories
	Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory.
	Revenue Recognition
	The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals or with the field representatives. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.
	Patent Costs
	The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets. The Company capitalized approximately $201,000 of patent costs during the first three months of 2015. The Company capitalized approximately $168,000 of patent costs during the first three months of 2014.
	Treasury Stock
	The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.
	Recent Accounting Pronouncements
	The Company considers the applicability and impact of all ASUs issued effective and not yet effective. In May 2014, the Financial Accounting Standards Board issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2016 and interim periods therein and requires expanded disclosures. We are currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements. All other ASUs issued effective and not yet effective for the three months ended March 31, 2015, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.

Liquidity_and_Managements_Plan

Liquidity and Management's Plans	3 Months Ended
	Mar. 31, 2015
Liquidity and management's plans [Abstract]
Liquidity and Management's Plans	Liquidity and Management’s Plans
	As of March 31, 2015, the Company had approximately $38,696,000 of cash and cash equivalents.  The Company reported total current assets of approximately $82,286,000 and current liabilities of approximately $18,460,000 as of March 31, 2015.  The Company believes that its anticipated cash from operating and financing activities, and existing cash and cash equivalents will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next twelve months.

Short_Term_Investments

Short Term Investments	3 Months Ended
	Mar. 31, 2015
Cash and Cash Equivalents [Abstract]
Short Term Investments	Short Term Investments
	Short term investments consist of approximately $6,000,000 of FDIC insured certificates of deposit held with various financial institutions as of March 31, 2015. Short term investments consisted of approximately $5,750,000 of FDIC insured certificates of deposit at December 31, 2014. The cost of these instruments approximates their fair market value at March 31, 2015

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories
	Inventories consisted of the following items as of March 31, 2015, and December 31, 2014 (in thousands):
		March 31, 2015			December 31, 2014
	Raw materials	$	251		$	255
	Work in process	2,632			3,419
	Finished goods	1,917			1,986
	Inventory, gross	4,800			5,660
	Reserve for obsolescence	(552		)	(527		)
	Inventory, net	$	4,248		$	5,133

Investments

Investments	3 Months Ended
	Mar. 31, 2015
Investments, All Other Investments [Abstract]
Investments	Investments
	Investments consist of FDIC insured certificates of deposit with various U.S. financial institutions that mature in May 2016. The balances as of March 31, 2015, and December 31, 2014 were approximately $2,500,000 and $3,250,000, respectively and the cost approximates fair market value.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment
	Property and equipment consist of the following as of March 31, 2015, and December 31, 2014 (in thousands):
		March 31,			December 31,
		2015			2014
	Leasehold improvements	$	2,589		$	2,559
	Lab and clean room equipment	3,176			3,040
	Furniture and office equipment	2,600			2,398
	Construction in progress	1,928			949
	Property and equipment, gross	10,293			8,946
	Less accumulated depreciation	(3,853		)	(3,499		)
	Property and equipment, net	$	6,440		$	5,447
	Included in net property and equipment is approximately $427,000 of equipment covered under capital leases. The corresponding liability of approximately $221,000 is included in other liabilities in the accompanying Condensed Consolidated Balance Sheets. Interest rates for these leases range from approximately 3% to 12% with maturity dates from September 2016 to January 2018.
	Also included is approximately $1.0 million in leasehold improvements paid for by the landlord of the Company's main facility with a corresponding liability included in other liabilities which is amortized over the term of the lease.
	Depreciation expense for the three months ended March 31, 2015 and 2014, was approximately $354,000 and $263,000, respectively.

Intangible_Assets_and_Royalty_

Intangible Assets and Royalty Agreement	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Royalty Agreement	Intangible Assets and Royalty Agreement
	Intangible assets are summarized as follows (in thousands):
		Weighted		31-Mar-15			31-Dec-14
		Average
		Amortization
		Lives
				Cost			Cost
	Licenses (a) (b)	10 years		$	1,009		$	1,009
	Patents & Know How (b)	17 years		7,893			7,891
	Customer & Supplier Relationships (b)	14 years		3,761			3,761
	Tradenames & Trademarks (b)	indefinite		1,008			1,008
	In Process Research & Development (b)	n/a		25			25
	Patents in Process (c)	n/a		1,281			1,082
	Total			14,977			14,776
	Less Accumulated amortization			(4,164		)	(3,931		)
	Net			$	10,813		$	10,845
	(a)	On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of March 31, 2015, this license had a remaining net book value of approximately $184,000.
	(b)	On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the three months ended March 31, 2015 an additional $2,333 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.
	(c)	Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
	Amortization expense for the three months ended March 31, 2015 and 2014, was approximately $233,000, and $231,000, respectively.
	Expected future amortization of intangible assets as of March 31, 2015, is as follows (in thousands):
	Year ending December 31,	Estimated
		Amortization
		Expense
	2015 (a)	$	697
	2016	929
	2017	840
	2018	830
	2019	830
	Thereafter	5,679
		$	9,805
	(a) Estimated amortization expense for the year ending December 31, 2015, includes only amortization to be recorded after March 31, 2015.

Net_Income_Loss_Per_Share

Net Income (Loss) Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income (Loss) Per Share
	Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock, and warrants using the treasury stock method.
	The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except share data):
		Three Months Ended March 31,
		2015		2014
	Net income (loss)	$	4,087	$	(922	)
	Denominator for basic earnings per share - weighted average shares	105,820,335		105,358,694
	Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)	7,818,216		—
	Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	113,638,551		105,358,694
	Income (loss) per common share - basic	$	0.04	$	(0.01	)
	Income (loss) per common share - diluted	$	0.04	$	(0.01	)
	(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method for the three months ended March 31, 2015, are as follows:
	Outstanding Stock Options	7,392,355
	Outstanding Warrants	42,400
	Restricted Stock Awards	383,461
		7,818,216
	Securities outstanding for the three months ended March 31, 2014 were excluded from the computation of diluted earnings per share because they would have been anti-dilutive.

Equity

Equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Equity	Equity
	Stock Incentive Plans
	The Company has three share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at March 31, 2015 totaled 195,000.  On July 28, 2014, the Company's shareholders approved 4,000,000 additional shares to be made available under the 2006 Plan, bringing the maximum number of shares of common stock that can be issued under the 2006 Plan to 26,500,000 at March 31, 2015.
	Activity with respect to the stock options is summarized as follows:
		Number		Weighted-				Weighted-Average	Aggregate
		of		Average				Remaining	Intrinsic
		Shares		Exercise				Contractual Term	Value
				Price				(in years)
	Outstanding at January 1, 2015	16,474,227		$	3.43
	Granted	57,600		9.55
	Exercised	(760,156	)	1.68
	Unvested options forfeited	(140,996	)	6.43
	Outstanding at March 31, 2015	15,630,675		3.51				7.1	$	107,655,519
	Vested at March 31, 2015	10,940,415		2.51				6.6	$	86,267,905
	Vested or expected to vest at March 31, 2015 (a)	15,419,100		$	3.47			7.1	$	106,858,970
	(a)	Includes forfeiture adjusted unvested shares.
	The intrinsic value of the options exercised during the three months ended March 31, 2015, was approximately $6,402,516.
	Following is a summary of stock options outstanding and exercisable at March 31, 2015:
		Options Outstanding							Options Exercisable
	Range of Exercise Prices	Number outstanding		Weighted-Average		Weighted-			Number Exercisable		Weighted-
				Remaining		Average					Average
				Contractual Term		Exercise					Exercise Price
				(in years)		Price
	$0.50 - $0.76	441,429		4.1		$	0.72		441,429		$	0.72
	$0.87 - $1.35	5,544,494		6.4		1.2			5,519,492		1.2
	$1.40 - $2.29	1,361,717		4.7		1.64			1,240,048		1.65
	$2.33 - $3.75	1,668,922		7.4		2.77			1,015,730		2.78
	$3.95 - $5.99	3,246,711		8.1		5.18			1,790,263		5.1
	$6.02 - $9.13	3,184,802		8.5		7.06			933,453		7.07
	$9.22- $10.99	182,600		9.7		10.13			—		—
		15,630,675		7.1		$	3.51		10,940,415		$	2.51
	Total unrecognized compensation expense related to granted stock options at March 31, 2015, was approximately $12,426,694 and will be charged to expense ratably through February 2018.
	The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method,” which computes expected term as the mid point between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company's lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.
	The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:
		Three Months Ended March 31,
		2015		2014
	Expected volatility	56.8- 58.1%		64.1 - 64.5%
	Expected life (in years)	6		6
	Expected dividend yield	—		—
	Risk-free interest rate	1.57% - 1.66%		1.69% - 1.96%
	The weighted-average grant date fair value for options granted during the three months ended March 31, 2015, was approximately $5.13.
	Restricted Stock Awards
	Activity with respect to restricted stock awards is summarized as follows:
		Number		Weighted-Average Grant Date
		of		Fair Value
		Shares
	Unvested at January 1, 2015	1,228,898		$7.16
	Granted	1,290,858		9.52
	Vested	(232,691	)	6.54
	Forfeited	(715	)	7.24
	Unvested at March 31, 2015	2,286,350		$8.56
	As of March 31, 2015, there was approximately $17,989,017 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.6 years, which approximates the remaining vesting period of these grants. All shares noted above as unvested are considered issued and outstanding at March 31, 2015.
	For the three months ended March 31, 2015 and 2014, the Company recognized stock-based compensation as follows (in thousands):
		Three Months Ended March 31,
		2015			2014
	Cost of sales	$	95		$	97
	Research and development	186			160
	Selling, general and administrative	3,652			2,115
		$	3,933		$	2,372
	Warrants
	As of March 31, 2015, the Company had 42,400 common stock warrants with an exercise price of $1.09 outstanding representing compensation to consultants and advisors in connection with previous debt offerings. The warrants expire in December 2016 and are classified as equity.
	Treasury Stock
	On May 12, 2014, the Company announced that its Board of Directors had authorized the repurchase of up to $10,000,000 of its common stock from time to time, through December 31, 2014. On December 12, 2014, the Board extended this program until December 31, 2015. On January 5, 2015, the Board increased the authorization under the program to $20,000,000. The timing and amount of future repurchases, if any, will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
	For the three months ended March 31, 2015, the Company purchased 1,359,753 shares of its common stock for an aggregate purchase price of approximately $12,254,000 before brokerage commissions of approximately $41,000. As of March 31, 2015, the Company had approximately $2,162,000 remaining under the repurchase program.
Additionally, for the three months ended March 31, 2015, the Company reissued 1,369,108 shares from the Treasury for restricted stock grants and stock option exercises with an aggregate carrying value of $9,310,268.

Income_taxes

Income taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income taxes	Income taxes
	The effective tax rates for continuing operations of 3.4% and (1.1%), respectively, for the three months ended March 31, 2015 and March 31, 2014, were determined using an estimated annual effective tax rate and after considering any discrete items for such periods. Due to a valuation allowance against the Company's U.S. deferred tax assets, the effective tax rate for the three months ended March 31, 2015, does not include the expense of the current period U.S. taxable income. A valuation allowance is recorded to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that a portion or none of the deferred tax assets will be realized.  After consideration of all the evidence, including reversal of deferred tax liabilities, future taxable income and other factors, management has determined that a full valuation allowance is necessary as of March 31, 2015. As a result, income tax expense for the three months ended March 31, 2015, is primarily due to income tax expense in certain state jurisdictions.
	As a result of anticipated profitability for the year and positive trends in the foreseeable future, the Company may release all or a portion of this valuation allowance by the end of 2015. However, the exact timing and amount of the valuation allowance released are subject to change based on the level of profitability that the Company is able to actually achieve for the year and its visibility into future period results. The potential release of this valuation allowance during 2015 would have a material impact on the Company's recorded tax expense in the period of reversal. The Company will release this valuation allowance when management determines that it is more likely than not that its deferred tax asset will be realized.

Supplemental_disclosure_of_cas

Supplemental disclosure of cash flow and non-cash investing and financing activities	3 Months Ended
	Mar. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental disclosure of cash flow and non-cash investing and financing activities	Supplemental disclosure of cash flow and non-cash investing and financing activities:
	Selected cash payments, receipts, and noncash activities are as follows (in thousands):
		Three Months Ended March 31,
		2015		2014
	Cash paid for interest	$	14	$	21
	Income taxes paid	363		7
	Stock issuance of 11,321 shares in exchange for services performed	71		—

Contractual_Commitments_and_Co

Contractual Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Contractual Commitments and Contingencies	Contractual Commitments and Contingencies
	Contractual Commitments
	In addition to the Capital Leases noted above in Note 7, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next four years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space and to various charitable organizations. The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):
	12-month period ended March 31
	2016	$	2,326
	2017	1,502
	2018	1,520
	2019	1,192
	Thereafter	—
		$	6,540
	Rent expense for the three months ended March 31, 2015 and 2014, was approximately $284,000 and $282,000, respectively, and is allocated among cost of sales, research and development, and selling, general and administrative expenses.
	Letters of Credit
	As a condition of the lease for the Company's main facility, the Company is obligated under standby letters of credit in the amount of approximately $500,000. These obligations are reduced at various times over the life of the lease.
	FDA Untitled Letter and Related Litigation
	Initially, MiMedx processed its tissue allografts in only one form, which was a sheet form. In 2011, MiMedx introduced a micronized form of its sheet allografts.
	The FDA has specific regulations governing human cells, tissues and cellular and tissue-based products, or HCT/Ps. An HCT/P is a product containing or consisting of human cells or tissue intended for transplantation into a human patient. If an HCT/P meets the criteria for regulation solely under Section 361 of the Public Health Service Act (so-called “361 HCT/Ps”), no FDA review for safety and effectiveness under a drug, device, or biological product marketing application is required.
	MiMedx believes that all of its tissue products qualify as 361 HCT/Ps. On August 28, 2013, however, the FDA issued an Untitled Letter alleging that the Company’s micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market the micronized products.
	In November 2013, the FDA clarified the basis for its position regarding the micronized products. Specifically, the FDA explained its belief that “[c]ryo-milling cut, dehydrated amniotic/chorionic membrane results in a micron-sized powder and the loss of the tensile strength and elasticity that are essential characteristics of the original amniotic/chorionic tissue relating to its utility to function as a ‘physical membrane’ (i.e. covering, barrier).” The Company responded to the FDA that while it does not agree with the FDA’s position, it understands the FDA’s interest in further regulating this emerging technology. Accordingly, the Company proposed to the FDA that it would pursue the Investigational New Drug (“IND”) and Biologics License Application (“BLA”) process for certain micronized products, and, in parallel, also proposed to enter into negotiations with the FDA on a plan to transition the micronized products to licensed biological products and continue to market the micronized products under specific conditions.
	On July 22, 2014, the Company filed its first IND application with the FDA. The application was allowed, paving the way for a Phase IIB clinical trial of its micronized product for a specified indication of use in anticipation of a BLA, which the Company expects to submit at a future date.  The clinical trial is expected to enroll approximately 150 patients in 10 - 20 clinical sites in the U.S. The Company initiated the trial in March of 2015.
	The Company also requested a transition agreement to allow it to continue to market its current micronized products for certain specified uses while pursuing one or more BLAs. The Agency continues to assert that the current form of the Company’s micronized products are more than minimally manipulated and therefore are not eligible for marketing solely under Section 361 of the Public Health Service Act. The Company has conducted tests and has engaged independent laboratories to conduct tests that confirm that tensile strength and modulus of elasticity are not diminished by the process used by the Company to create its micronized products.
	On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially the draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to MiMedx 16 months earlier.
	The period for submitting comments on the Draft Guidance expired on February 23, 2015. The Company has submitted comments to the Draft Guidance asserting that the Draft Guidance represents agency action that goes far beyond FDA’s statutory authority, is inconsistent with existing HCT/ P regulations and FDA’s prior positions, and is internally inconsistent and is scientifically unsound. Additionally, the Company asked the FDA to allow MiMedx to continue to market its micronized products until the guidance or regulations as the case may be have been fully vetted through a process of notice and comment rule making. Preliminarily, FDA has indicated that it intends to issue for comment Draft Guidance on homologous use later this year and that industry and other interested parties will have an opportunity to comment on both guidance documents as a whole at that time.
	If the FDA does allow the Company to continue to market a micronized form of its sheet allografts either prior to or after finalization of the Draft Guidance, it may impose conditions, such as labeling restrictions and compliance with Current Good Manufacturing Practices (“cGMP”). It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the Draft Guidance and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately 14% of the Company's revenues in 2014.
	Following the publication of the Untitled Letter from the FDA regarding the Company’s micronized products in September 2013, the trading price of the Company’s stock dropped sharply and several purported class action lawsuits were filed against the Company and certain of its executive officers asserting violations of the Securities Act of 1933 and the Securities Exchange Act of 1934 with respect to various statements and alleged omissions related to the Company’s belief that its products were 361 HCT/Ps, including its micronized products. These cases have now all been removed to, and consolidated in, the United States District Court for the Northern District of Georgia. By order dated December 9, 2013, the Court approved the appointment of a lead plaintiff and a lead counsel. A Consolidated Amended Class Action Complaint, containing substantially the same causes of action and claims for relief as the initial complaints, was filed on January 27, 2014. The case is currently in the discovery phase. The Company currently believes that the outcome of this litigation will not have a material adverse impact on the Company's financial position or results of operations.
	OIG Subpoena And Other Shareholder Litigation
	In the fourth quarter of 2014, the Company received a subpoena from the Office of Inspector General, U.S. Department of Health and Human Services, or OIG, in connection with a civil investigation into matters primarily related to the Company's sales and marketing activities. In March 2015, the Company received notice from the Department of Justice that it declined at that time to intervene in the qui tam action that gave rise to the issuance of a subpoena. While it is still possible that the qui tam action could be brought privately by the relator and the government could opt to intervene in the qui tam action at a later date, the Company currently believes that the outcome of this litigation will not have a material adverse impact on the Company's financial condition or results of operations.
	On February 19, 2015, a separate purported class action lawsuit was filed against the Company and certain of its executive officers in the United States District Court for the Southern District of New York. The suit alleged violations of the Securities Act of 1933 and the Securities Exchange Act of 1934 with respect to various statements and alleged omissions related to the Company’s receipt of the subpoena discussed above. On April 22, 2015, the plaintiffs voluntarily dismissed this purported class action lawsuit against the Company.
	Patent Litigation
	On April 22, 2014, the Company filed a patent infringement lawsuit against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages. In addition to the allegations of infringement of certain of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. The suit was filed in the United States District Court for the Northern District of Georgia. In the suit, MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company’s patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the processor and Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, the defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity. On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts (“Bone Bank”) and Texas Human Biologics, Ltd. (“Biologics”) for permanent injunctive relief and unspecified damages. The lawsuit was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company’s patents through the manufacturing and sale of tissue graft products. The defendants have denied the allegations in the Complaint. They also have raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. The lawsuits currently are in the discovery and claim construction phases. In addition to defending the pending district court litigations, to avoid the high burden of proof required to prove invalidity of the Company's patent claims in the district court litigation, the defendants have filed several requests for inter-partes review by the Patent Trial and Appeal Board seeking to invalidate some of the Company's patent claims.
	On March 2, 2015, the Company filed a patent infringement lawsuit against Nutech Medical, Inc. (“Nutech”) and DCI Donor Services, Inc. (“DCI”) for permanent injunctive relief and unspecified damages.  This lawsuit has been filed in the United States District Court for the Northern District of Alabama.  The lawsuit alleges that Nutech and DCI have infringed and continue to infringe MiMedx’s patents through the manufacture, use, sale, and/or offering of their tissue graft product.  The lawsuit also asserts that Nutech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events
	On April 27, 2015, the Company's Board of Directors increased the authorization under the share repurchase program from $20,000,000 to $30,000,000.

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts	3 Months Ended
	Mar. 31, 2015
Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	Schedule II Valuation and Qualifying Accounts
	MIMEDX GROUP, INC. AND SUBSIDIARIES
	SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
	Three Months Ended March 31, 2015 and 2014 (in thousands)
		Balance at		Additions charged to Expense or Revenue		Deductions			Balance at
		Beginning of Period				and write-offs			End of Period
	For the Quarter ended March 31, 2015
	Allowance for doubtful accounts	$	1,750	$	260	$	—		$	2,010
	Allowance for product returns	841		709		(606		)	944
	Allowance for obsolescence	527		130		(105		)	552
	For the Quarter ended March 31, 2014
	Allowance for doubtful accounts	$	407	$	125	$	(6	)	$	526
	Allowance for product returns	215		201		(111		)	305
	Allowance for obsolescence	322		24		(23		)	323

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Use of estimates	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable	Accounts Receivable
	Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
	The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.
Inventories	Inventories
	Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. The Company assesses the valuation of its inventory on a periodic basis and makes adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for the Company's excess inventory charge. The Company's excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory.
Revenue Recognition	Revenue Recognition
	The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all other revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals or with the field representatives. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.
Patent Costs	Patent Costs
	The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company and are included in Intangible Assets in the Condensed Consolidated Balance Sheets. The Company capitalized approximately $201,000 of patent costs during the first three months of 2015. The Company capitalized approximately $168,000 of patent costs during the first three months of 2014.
Treasury Stock	Treasury Stock
	The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a first - in first - out (FIFO) basis.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	The Company considers the applicability and impact of all ASUs issued effective and not yet effective. In May 2014, the Financial Accounting Standards Board issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2016 and interim periods therein and requires expanded disclosures. We are currently assessing the impact the adoption of ASU 2014-09 will have on our condensed consolidated financial statements. All other ASUs issued effective and not yet effective for the three months ended March 31, 2015, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventory	Inventories consisted of the following items as of March 31, 2015, and December 31, 2014 (in thousands):
		March 31, 2015			December 31, 2014
	Raw materials	$	251		$	255
	Work in process	2,632			3,419
	Finished goods	1,917			1,986
	Inventory, gross	4,800			5,660
	Reserve for obsolescence	(552		)	(527		)
	Inventory, net	$	4,248		$	5,133

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment consist of the following as of March 31, 2015, and December 31, 2014 (in thousands):
		March 31,			December 31,
		2015			2014
	Leasehold improvements	$	2,589		$	2,559
	Lab and clean room equipment	3,176			3,040
	Furniture and office equipment	2,600			2,398
	Construction in progress	1,928			949
	Property and equipment, gross	10,293			8,946
	Less accumulated depreciation	(3,853		)	(3,499		)
	Property and equipment, net	$	6,440		$	5,447

Intangible_Assets_and_Royalty_1

Intangible Assets and Royalty Agreement (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets activity summary	Intangible assets are summarized as follows (in thousands):
		Weighted		31-Mar-15			31-Dec-14
		Average
		Amortization
		Lives
				Cost			Cost
	Licenses (a) (b)	10 years		$	1,009		$	1,009
	Patents & Know How (b)	17 years		7,893			7,891
	Customer & Supplier Relationships (b)	14 years		3,761			3,761
	Tradenames & Trademarks (b)	indefinite		1,008			1,008
	In Process Research & Development (b)	n/a		25			25
	Patents in Process (c)	n/a		1,281			1,082
	Total			14,977			14,776
	Less Accumulated amortization			(4,164		)	(3,931		)
	Net			$	10,813		$	10,845
	(a)	On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of March 31, 2015, this license had a remaining net book value of approximately $184,000.
	(b)	On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the three months ended March 31, 2015 an additional $2,333 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.
	(c)	Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
Estimated future amortization expense for intangible assets	Expected future amortization of intangible assets as of March 31, 2015, is as follows (in thousands):
	Year ending December 31,	Estimated
		Amortization
		Expense
	2015 (a)	$	697
	2016	929
	2017	840
	2018	830
	2019	830
	Thereafter	5,679
		$	9,805
	(a) Estimated amortization expense for the year ending December 31, 2015, includes only amortization to be recorded after March 31, 2015.

Net_Income_Loss_Per_Share_Tabl

Net Income (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss per Share	The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except share data):
		Three Months Ended March 31,
		2015		2014
	Net income (loss)	$	4,087	$	(922	)
	Denominator for basic earnings per share - weighted average shares	105,820,335		105,358,694
	Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)	7,818,216		—
	Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	113,638,551		105,358,694
	Income (loss) per common share - basic	$	0.04	$	(0.01	)
	Income (loss) per common share - diluted	$	0.04	$	(0.01	)
	(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method for the three months ended March 31, 2015, are as follows:
	Outstanding Stock Options	7,392,355
	Outstanding Warrants	42,400
	Restricted Stock Awards	383,461
		7,818,216
	Securities outstanding for the three months ended March 31, 2014 were excluded from the computation of diluted earnings per share because they would have been anti-dilutive.

Equity_Tables

Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stock Options Activity	Activity with respect to the stock options is summarized as follows:
		Number		Weighted-				Weighted-Average	Aggregate
		of		Average				Remaining	Intrinsic
		Shares		Exercise				Contractual Term	Value
				Price				(in years)
	Outstanding at January 1, 2015	16,474,227		$	3.43
	Granted	57,600		9.55
	Exercised	(760,156	)	1.68
	Unvested options forfeited	(140,996	)	6.43
	Outstanding at March 31, 2015	15,630,675		3.51				7.1	$	107,655,519
	Vested at March 31, 2015	10,940,415		2.51				6.6	$	86,267,905
	Vested or expected to vest at March 31, 2015 (a)	15,419,100		$	3.47			7.1	$	106,858,970
	(a)	Includes forfeiture adjusted unvested shares.
Stock Options Outstanding and Exercisable	Following is a summary of stock options outstanding and exercisable at March 31, 2015:
		Options Outstanding							Options Exercisable
	Range of Exercise Prices	Number outstanding		Weighted-Average		Weighted-			Number Exercisable		Weighted-
				Remaining		Average					Average
				Contractual Term		Exercise					Exercise Price
				(in years)		Price
	$0.50 - $0.76	441,429		4.1		$	0.72		441,429		$	0.72
	$0.87 - $1.35	5,544,494		6.4		1.2			5,519,492		1.2
	$1.40 - $2.29	1,361,717		4.7		1.64			1,240,048		1.65
	$2.33 - $3.75	1,668,922		7.4		2.77			1,015,730		2.78
	$3.95 - $5.99	3,246,711		8.1		5.18			1,790,263		5.1
	$6.02 - $9.13	3,184,802		8.5		7.06			933,453		7.07
	$9.22- $10.99	182,600		9.7		10.13			—		—
		15,630,675		7.1		$	3.51		10,940,415		$	2.51
Fair Value of Options, Valuation Assumptions	The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:
		Three Months Ended March 31,
		2015		2014
	Expected volatility	56.8- 58.1%		64.1 - 64.5%
	Expected life (in years)	6		6
	Expected dividend yield	—		—
	Risk-free interest rate	1.57% - 1.66%		1.69% - 1.96%
Restricted Stock Awards Roll Forward	Activity with respect to restricted stock awards is summarized as follows:
		Number		Weighted-Average Grant Date
		of		Fair Value
		Shares
	Unvested at January 1, 2015	1,228,898		$7.16
	Granted	1,290,858		9.52
	Vested	(232,691	)	6.54
	Forfeited	(715	)	7.24
	Unvested at March 31, 2015	2,286,350		$8.56
Allocation of Share-based Compensation	For the three months ended March 31, 2015 and 2014, the Company recognized stock-based compensation as follows (in thousands):
		Three Months Ended March 31,
		2015			2014
	Cost of sales	$	95		$	97
	Research and development	186			160
	Selling, general and administrative	3,652			2,115
		$	3,933		$	2,372

Supplemental_disclosure_of_cas1

Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables)	3 Months Ended
	Mar. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities	Selected cash payments, receipts, and noncash activities are as follows (in thousands):
		Three Months Ended March 31,
		2015		2014
	Cash paid for interest	$	14	$	21
	Income taxes paid	363		7
	Stock issuance of 11,321 shares in exchange for services performed	71		—

Contractual_Commitments_and_Co1

Contractual Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Estimated Annual Lease, Royalty and Employment Agreement Expenses	In addition to the Capital Leases noted above in Note 7, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next four years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space and to various charitable organizations. The estimated annual lease payments, meeting space and charitable organization commitments are as follows (in thousands):
	12-month period ended March 31
	2016	$	2,326
	2017	1,502
	2018	1,520
	2019	1,192
	Thereafter	—
		$	6,540

Basis_of_Presentation_Details

Basis of Presentation (Details)	3 Months Ended
	Mar. 31, 2015
	segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of business segments	1

Significant_Accounting_Policie2

Significant Accounting Policies (Details) (Patents [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net of accumulated amortization	$201	$168

Liquidity_and_Managements_Plan1

Liquidity and Management's Plans (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Liquidity and management's plans [Abstract]
Cash and cash equivalents	$38,696	$46,582	$43,019	$44,078
Total current assets	82,286	85,677
Total current liabilities	$18,460	$18,404

Short_Term_Investments_Details

Short Term Investments (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Investment [Line Items]
Cash and cash equivalents	$38,696	$46,582	$43,019	$44,078
Short term investments	6,000	5,750
Certificates of Deposit
Investment [Line Items]
Short term investments	$6,000	$5,750

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$251	$255
Work in process	2,632	3,419
Finished goods	1,917	1,986
Inventory, gross	4,800	5,660
Reserve for obsolescence	-552	-527
Inventory, net	$4,248	$5,133

Investments_Details

Investments (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Investments, All Other Investments [Abstract]
Investments	$2,500	$3,250

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Property and equipment [Line Items]
Property and equipment, gross	$10,293		$8,946
Less accumulated depreciation	-3,853		-3,499
Property and equipment, net	6,440		5,447
Other liabilities	1,244		1,526
Capital Leases Interest Rate Effective Percentage Minimum	3.00%
Capital Leases Interest Rate Effective Percentage Maximum	12.00%
Depreciation	354	263
Leasehold improvements
Property and equipment [Line Items]
Property and equipment, gross	2,589		2,559
Lab and clean room equipment
Property and equipment [Line Items]
Property and equipment, gross	3,176		3,040
Furniture and office equipment
Property and equipment [Line Items]
Property and equipment, gross	2,600		2,398
Construction in progress
Property and equipment [Line Items]
Property and equipment, gross	1,928		949
Assets Held under Capital Leases
Property and equipment [Line Items]
Property and equipment, net	427
Other liabilities	221
Leasehold Improvements Paid by Others
Property and equipment [Line Items]
Property and equipment, net	$1,000

Intangible_Assets_and_Royalty_2

Intangible Assets and Royalty Agreement (Details) (USD $)	3 Months Ended			0 Months Ended
	Mar. 31, 2015		Mar. 31, 2014	Jan. 29, 2007	Dec. 31, 2014		Jan. 05, 2011
Finite-Lived Intangible Assets [Line Items]
Total	$14,977,000				$14,776,000
Less Accumulated amortization	-4,164,000				-3,931,000
Net	10,813,000				10,845,000
Net book value	9,805,000
Amortization of intangible assets	233,000		231,000
Estimated future amortization expense [Abstract]
2015	697,000	[1]
2016	929,000
2017	840,000
2018	830,000
2019	830,000
Thereafter	5,679,000
Net book value	9,805,000
Licenses
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives	10 years	[2],[3]
Gross Carrying Value	1,009,000	[2],[3]			1,009,000	[2],[3]
Licenses | Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.
Finite-Lived Intangible Assets [Line Items]
Acquisition price				996,000
Maximum time of approval				30 days
Contingent payments to licensor	200,000
Contingent royalty to be paid to licensor (in hundredths)	3.00%
Annual royalty payment				50,000
Net book value	184,000
Estimated future amortization expense [Abstract]
Net book value	184,000
Licenses | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value							13,000
Patents & Know How
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives	17 years	[2]
Gross Carrying Value	7,893,000	[2]			7,891,000	[2]
Patents & Know How | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value							7,690,000
Finite-Lived Intangible Assets, Costs	2,333
Customer & Supplier Relationships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives	14 years	[2]
Gross Carrying Value	3,761,000	[2]			3,761,000	[2]
Customer & Supplier Relationships | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value							3,761,000
Tradenames & Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value, Indefinite Lived	1,008,000	[2]			1,008,000	[2]
Tradenames & Trademarks | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value, Indefinite Lived							1,008,000
In Process Research & Development
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value, Indefinite Lived	25,000	[2]			25,000	[2]
In Process Research & Development | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value, Indefinite Lived							25,000
Patents in Process
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value, Indefinite Lived	$1,281,000	[4]			$1,082,000	[4]
[1]	Estimated amortization expense for the year ending December 31, 2015, includes only amortization to be recorded after March 31, 2015.
[2]	On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the three months ended March 31, 2015 an additional $2,333 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.
[3]	On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of March 31, 2015, this license had a remaining net book value of approximately $184,000
[4]	Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.

Net_Income_Loss_Per_Share_Deta

Net Income (Loss) Per Share (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015		Mar. 31, 2014
Computation of basic and diluted net loss per share [Abstract]
Net income	$4,087		($922)
Denominator for basic earnings per share - weighted average shares	105,820,335		105,358,694
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (in shares)	7,818,216	[1]	0	[1]
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	113,638,551		105,358,694
Income (loss) per common share - basic	$0.04		($0.01)
Income (loss) per common share - diluted	$0.04		($0.01)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,818,216
Outstanding Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,392,355
Outstanding Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	42,400
Restricted Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	383,461
[1]	Securities outstanding that are included in the computation above, utilizing the treasury stock method for the three months ended March 31, 2015, are as follows:Outstanding Stock Options7,392,355Outstanding Warrants42,400Restricted Stock Awards383,461B 7,818,216Securities outstanding for the three months ended March 31, 2014 were excluded from the computation of diluted earnings per share because they would have been anti-dilutive.

Equity_Details

Equity (Details) (USD $)	3 Months Ended					8 Months Ended
	Mar. 31, 2015		Mar. 31, 2015		Mar. 31, 2014	Jan. 04, 2015
			plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share-based compensation plans			3
Outstanding assumed options (in shares)	195,000		195,000
Additional shares authorized by Board of Directors (in shares)			4,000,000
Shares authorized (in shares)	26,500,000		26,500,000
Total unrecognized compensation expense	$12,426,694		$12,426,694
Number of shares [Roll forward]
Outstanding, beginning of period (in shares)			16,474,227
Granted (in shares)			57,600
Exercised (in shares)			-760,156
Unvested options forfeited (in shares)			-140,996
Outstanding, end of period (in shares)	15,630,675		15,630,675
Vested at end of period (in shares)	10,940,415		10,940,415
Exercisable options, vested and expected to vest (in shares)	15,419,100	[1]	15,419,100	[1]
Weighted-Average Exercise Price [Roll forward]
Outstanding, weighted average exercise price, beginning of period (in dollars per share)			$3.43
Granted, weighted average exercise price (in dollars per share)			$9.55
Exercised, weighted average exercise price (in dollars per share)			$1.68
Unvested options forfeited weighted-average exercise price (in dollars per share)			$6.43
Outstanding, weighted average exercise price, end of period (in dollars per share)	$3.51		$3.51
Vested at end of period weighted average exercise price (in dollars per share)	$2.51		$2.51
Vested and expected to vest, weighted average exercise price (in dollars per share)	$3.47	[1]	$3.47	[1]
Stock options, additional disclosures [Abstract]
Vested at end of period weighted average remaining contractual term			6 years 7 months 6 days
Vested and expected to vest, weighted average remaining contractual term			7 years 1 month 6 days	[1]
Outstanding intrinsic value	107,655,519		107,655,519
Vested at end of period aggregate intrinsic value	86,267,905		86,267,905
Vested and expected to vest, aggregate intrinsic value	106,858,970	[1]	106,858,970	[1]
Exercised options, intrinsic value			6,402,516
Number of outstanding options (in shares)	15,630,675		15,630,675
Outstanding Options, weighted average remaining contractual term			7 years 1 month 6 days
Outstanding Options, weighted average exercise price (in dollars per share)	$3.51		$3.51
Number of exercisable options (in shares)	10,940,415		10,940,415
Exercisable Options, weighted average exercise price (in dollars per share)	$2.51		$2.51
Fair value options valuation assumptions [Abstract]
Expected volatility Minimum			56.80%		64.10%
Expected volatility Maximum			58.10%		64.50%
Expected life (in years)			6 years		6 years
Expected dividend yield			0.00%		0.00%
Risk-free interest rate Minimum			1.57%		1.69%
Risk-free interest rate Maximum			1.66%		1.96%
Share-based Compensation [Abstract]
Share-based compensation expense			3,933,000		2,372,000
Weighted-average grant date fair value for options granted during the period (in dollars per share)			$5.13
Weighted- Average Grant Date Fair Value
Authorized share amount for repurchase	20,000,000					10,000,000
Stock repurchase (in shares)			1,359,753
Shares repurchased, value			12,254,000
Brokerage commissions			41,000
Remaining authorizations under the repurchase program			2,162,000
Shares reissued from the treasury			1,369,108
Shares reissued from the treasury, value			9,310,268
Warrants
Weighted- Average Grant Date Fair Value
Warrants outstanding (in shares)	42,400		42,400
Warrants outstanding (in dollars per share)	1.09		1.09
Cost of Products Sold
Share-based Compensation [Abstract]
Share-based compensation expense			95,000		97,000
Research and Development
Share-based Compensation [Abstract]
Share-based compensation expense			186,000		160,000
Selling, General and Administrative
Share-based Compensation [Abstract]
Share-based compensation expense			3,652,000		2,115,000
$0.50 - $0.76
Stock options, additional disclosures [Abstract]
Exercise Price Range, lower range limit (in dollars per share)			$0.50
Exercise Price Range, upper range limit (in dollars per share)			$0.76
Number of outstanding options (in shares)	441,429		441,429
Outstanding Options, weighted average remaining contractual term			4 years 1 month 6 days
Outstanding Options, weighted average exercise price (in dollars per share)	$0.72		$0.72
Number of exercisable options (in shares)	441,429		441,429
Exercisable Options, weighted average exercise price (in dollars per share)	$0.72		$0.72
$0.87 - $1.35
Stock options, additional disclosures [Abstract]
Exercise Price Range, lower range limit (in dollars per share)			$0.87
Exercise Price Range, upper range limit (in dollars per share)			$1.35
Number of outstanding options (in shares)	5,544,494		5,544,494
Outstanding Options, weighted average remaining contractual term			6 years 4 months 24 days
Outstanding Options, weighted average exercise price (in dollars per share)	$1.20		$1.20
Number of exercisable options (in shares)	5,519,492		5,519,492
Exercisable Options, weighted average exercise price (in dollars per share)	$1.20		$1.20
$1.40 - $2.29
Stock options, additional disclosures [Abstract]
Exercise Price Range, lower range limit (in dollars per share)			$1.40
Exercise Price Range, upper range limit (in dollars per share)			$2.29
Number of outstanding options (in shares)	1,361,717		1,361,717
Outstanding Options, weighted average remaining contractual term			4 years 8 months 12 days
Outstanding Options, weighted average exercise price (in dollars per share)	$1.64		$1.64
Number of exercisable options (in shares)	1,240,048		1,240,048
Exercisable Options, weighted average exercise price (in dollars per share)	$1.65		$1.65
$2.33 - $3.75
Stock options, additional disclosures [Abstract]
Exercise Price Range, lower range limit (in dollars per share)			$2.33
Exercise Price Range, upper range limit (in dollars per share)			$3.75
Number of outstanding options (in shares)	1,668,922		1,668,922
Outstanding Options, weighted average remaining contractual term			7 years 4 months 24 days
Outstanding Options, weighted average exercise price (in dollars per share)	$2.77		$2.77
Number of exercisable options (in shares)	1,015,730		1,015,730
Exercisable Options, weighted average exercise price (in dollars per share)	$2.78		$2.78
$3.95 - $5.99
Stock options, additional disclosures [Abstract]
Exercise Price Range, lower range limit (in dollars per share)			$3.95
Exercise Price Range, upper range limit (in dollars per share)			$5.99
Number of outstanding options (in shares)	3,246,711		3,246,711
Outstanding Options, weighted average remaining contractual term			8 years 1 month 6 days
Outstanding Options, weighted average exercise price (in dollars per share)	$5.18		$5.18
Number of exercisable options (in shares)	1,790,263		1,790,263
Exercisable Options, weighted average exercise price (in dollars per share)	$5.10		$5.10
$6.02 - $9.13
Stock options, additional disclosures [Abstract]
Exercise Price Range, lower range limit (in dollars per share)			$6.02
Exercise Price Range, upper range limit (in dollars per share)			$9.13
Number of outstanding options (in shares)	3,184,802		3,184,802
Outstanding Options, weighted average remaining contractual term			8 years 6 months
Outstanding Options, weighted average exercise price (in dollars per share)	$7.06		$7.06
Number of exercisable options (in shares)	933,453		933,453
Exercisable Options, weighted average exercise price (in dollars per share)	$7.07		$7.07
$9.22- $10.99
Stock options, additional disclosures [Abstract]
Exercise Price Range, lower range limit (in dollars per share)			$9.22
Exercise Price Range, upper range limit (in dollars per share)			$10.99
Number of outstanding options (in shares)	182,600		182,600
Outstanding Options, weighted average remaining contractual term			9 years 8 months 12 days
Outstanding Options, weighted average exercise price (in dollars per share)	$10.13		$10.13
Number of exercisable options (in shares)	0		0
Exercisable Options, weighted average exercise price (in dollars per share)	$0		$0
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expenses expected to be recognized over a weighted-average period			2 years 7 months 6 days
Total unrecognized stock-based compensation related to time-based, nonvested restricted stock	$17,989,017		$17,989,017
Number of Shares
Beginning Balance			1,228,898
Granted			1,290,858
Vested			-232,691
Forfeited			-715
Ending Balance	2,286,350		2,286,350
Weighted- Average Grant Date Fair Value
Beginning Balance (in dollars per share)			$7.16
Granted (in dollars per share)			$9.52
Vested (in dollars per share)			$6.54
Forfeited (in dollars per share)			$7.24
Beginning Balance (in dollars per share)	$8.56		$8.56
[1]	Includes forfeiture adjusted unvested shares.

Income_taxes_Details

Income taxes (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Effective tax rate (as a percentage)	3.40%	1.10%

Supplemental_disclosure_of_cas2

Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Supplemental disclosure of cash flow and non-cash investing and financing activities [Abstract]
Cash paid for interest	$14	$21
Income taxes paid	363	7
Stock issuance of 11,321 shares in exchange for services performed	$71	$0
Shares issued for services performed (in shares)	11,321	0

Contractual_Commitments_and_Co2

Contractual Commitments and Contingencies (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
			patient
Loss Contingencies [Line Items]
Lease expiration period	4 years
Rent expense	$284,000	$282,000
Number of patients			150
Estimated annual lease, royalty, and employment agreement expenses [Abstract]
2016	2,326,000
2017	1,502,000
2018	1,520,000
2019	1,192,000
2020	0
Total Contractual commitments	6,540,000
Sales Revenue, Net | Product Concentration Risk
Loss Contingencies [Line Items]
Percentage of revenue			14.00%
Standby Letters of Credit
Loss Contingencies [Line Items]
Standby letters of credit	$500,000
Minimum
Loss Contingencies [Line Items]
Number of clinical sites			10
Maximum
Loss Contingencies [Line Items]
Number of clinical sites			20

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	3 Months Ended	8 Months Ended	0 Months Ended
	Mar. 31, 2015	Jan. 04, 2015	Apr. 27, 2015
Subsequent Event [Line Items]
Authorized share amount for repurchase	$20,000,000	$10,000,000
Subsequent Event
Subsequent Event [Line Items]
Authorized share amount for repurchase			$30,000,000

Schedule_II_Valuation_and_Qual1

Schedule II - Valuation and Qualifying Accounts (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Allowance for doubtful accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$1,750	$407
Additions charged to Expense or Revenue	260	125
Deductions and write-offs	0	-6
Balance at End of Period	2,010	526
Allowance for product returns
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	841	215
Additions charged to Expense or Revenue	709	201
Deductions and write-offs	-606	-111
Balance at End of Period	944	305
Allowance for obsolescence
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	527	322
Additions charged to Expense or Revenue	130	24
Deductions and write-offs	-105	-23
Balance at End of Period	$552	$323